Media Partners
Contact Us

The Organizing Committee of Pharma Manufacturing China Summit 2010

Tel: +86 21 5058 9600
Fax: +86 21 5058 5987



As a result patient treatment, there are 2.2 billion people in China in 2008 went to major hospitals. Among those, 60 million people were in hospital. 1/3 of all only wish to take medicine at home. It is even a phenomenon that Chinese people prepared family medicine box for common sickness like cold and hypertension. This is the first population in the world.

On the other hand, there are 380,000 pharmaceutical plants which they are only manufacture a few category pharmaceuticals currently in China. With the government procurement workload on 200 basic pharmaceuticals. According to SFDA's statistics, there are at least 40,000 pharmaceutical plants need to be certificated, inspected and evaluated synchronously. What a burden procurement plan is! "The oversea pharmaceutical manufacturers have not set up the plant in China yet is a big mistake!" said by the director of one pharmaceutical association in Shanghai.

Strategic Planning vs. Tactical Planning

The global PCM market was worth $26bn in 2007 and is expected to grow at a CAGR of 11.4% to reach $40bn by 2011. Contract manufacturing in India and China is forecast to expand at a CAGR of 20% through to 2011. Big Pharma are increasingly outsourcing manufacturing to low cost destinations due to cost and margin pressures, and India and China offer skilled manpower and a robust manufacturing infrastructure.

New cGMP, manufacturing facility project, pharmaceutical synthesis process, QA/QS, packaging, automation, pharmaceutical water system, API&CMO and other innovative technologies will be discussed in this event.

Furthermore, we would bring you some proactive thoughts on how to screen out qualified local partners? Any update regulations by state? What are the advantages in manufacturing China? Where is the best location for your plant? Beijing, Tianjin or Shanghai?

  • Strategically topics for the local and oversea pharmaceutical manufacturing giants
  • Global manufacturer - outsourcing concern and criteria?
  • Supporting the Sustainable Implementation of Operational Excellence
  • Local manufacturer's 3- 5 years strategy - How to moving up the value chain?
  • China latest drug reform, cGMP and technology transfer issues
  • Facilitating and Achieving QbD for Drug Products.
  • Green Manufacturing Strategies - Harnessing the Opportunities for Cost Reduction.
  • Process Improvement and Cost Reduction.
  • Developing a Flexible, Multi-Product Manufacturing strategy.
  • Creating the Pharmaceutical Facility of the Future.

12 OCT.

13 OCT.

13 OCT. Stream

14 OCT.


Global Giants vision & plans in
emerging marketsí» pharmaceutical

Pharma-manufacturing in China: Trends, Opportunities and Innovation


Site Tour
Shanghai EXPO Tour


Risk, return & growth: Capitalizing on chinaí»s growing
Pharmaceutical industry

Approaching Pharmaceutical Manufacturing Excellence



Oppland Corporation, all rights reserved